Is CYP2D6 destiny or just a small risk factor?

CYP2D6 is not destiny but a relevant risk factor. This gene encodes an enzyme responsible for metabolizing about 20–25% of common drugs, including antidepressants, antipsychotics, beta-blockers, and opioids like codeine. Polymorphisms (e.g., *4, *10, *17) classify individuals as poor, intermediate, extensive, or ultrarapid metabolizers. For certain drugs, especially codeine (a prodrug), the effect is clinically significant – ultrarapid metabolizers risk severe opioid toxicity. For other drugs, the influence is moderate and modulated by other genes (e.g., CYP2C19, CYP3A4), liver function, age, diet, and co-medications. Evidence is human-strong for specific drug-gene pairs but not universal. A single genetic test is insufficient for therapy decisions; it must be interpreted alongside full medication history and clinical context. Calling CYP2D6 'destiny' is misleading – it is one piece of a complex puzzle.